Jianfeng Group Lin2016 -028 (Announcement on Acceptance Notice of Drug Clinical Trial Application of Subsidiary Company)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2016-028
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Acceptance Notice of Subsidiary Drug Clinical Trial Application
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
1. Summary
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a controlling subsidiary of the Company, received the Notice of Acceptance of Drug Registration Application (Acceptance No.: CXHL1600201 Zhejiang) and (Acceptance No.: CXHL1600202 Zhejiang) issued by Zhejiang Food and Drug Administration. The clinical research application of deoxypodophyllotoxin for injection (acceptance number: CXHL1600202 Zhejiang) and its bulk drug (acceptance number: CXHL1600201 Zhejiang) (hereinafter collectively referred to as "DPT") developed by Jianfeng Pharmaceutical and China Pharmaceutical University has been accepted by Zhejiang Food and Drug Administration.
2. drug basic information content
(I) deoxypodophyllotoxin
drug name: deoxypodophyllotoxin
dosage form: non-preparation: bulk drug
packing specification: 2Kg
per bag application item: chemical drug: class 1
Application Stage: Clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd., China Pharmaceutical University
Application Acceptance Number: CXHL1600201 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
(II) Deoxypodophyllotoxin for Injection
Drug Name: Deoxypodophyllotoxin for Injection
Dosage Form: Preparation: Chinese Pharmacopoeia Dosage Form Injection
Specification: 100mg Package Specification: 1 bottle per box
Application Item: Chemical Drug: 1 Class
Application Stage: clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd. and China Pharmaceutical University
Application Acceptance Number: CXHL1600202 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
3. Drug Research and Development and Registration
DPT Project is a new anti-tumor drug developed by Jianfeng Pharmaceutical in cooperation with China Pharmaceutical University in March 112. Domestic and foreign listed alkaloids of similar drugs include: paclitaxel, vinorelbine. DPT indication/ function indication is tentatively designated as first-line and second-line treatment of lung cancer, breast cancer and gastric cancer; Especially for the treatment of the above tumors resistant to paclitaxel and vinorelbine.
DPT is currently in the stage of applying for clinical trial approval. After the clinical application of is accepted, the clinical research work can only be carried out after passing the review and approval of the State Food and Drug Administration (CFDA) and obtaining the clinical trial approval document. After the clinical trial is completed, the production can be applied, after passing the review and approval of CFDA and obtaining the drug production approval, can be produced and marketed.
Up to now, the accumulated research and development investment and other related expenditures of DPT project of Jianfeng Pharmaceutical Co., Ltd. are about 33 million yuan. The impact of
4. on listed companies and risk tips
DPT clinical application filed by the company has been accepted and will not have a significant impact on the company's recent operating results. After the clinical application of
is accepted, the clinical research work can only be carried out after passing the review and approval of CFDA and obtaining the clinical trial approval document. The results and time of the inspection, review and approval during the period are uncertain. Due to the long cycle and high risk of new drug research and development, the company will timely fulfill the obligation of information disclosure according to the progress of research and development. Please pay attention to the investment risk.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
August 25, 2016
More information
Peak re-listed China's top 100 cement production capacity Daye peak won the "smart factory leader"
On July 11-12, the 2022 China Cement Industry Summit and TOP100 Award Ceremony organized by China Cement Network, an authoritative media of China's cement industry, was held in Hangzhou. Jianfeng Group once again ranked among the top 100 cement clinker production capacity in China.
2022
08-04
On the afternoon of July 12, the party Committee of the group company held a special meeting attended by party Committee members, senior and middle-level management backbones, heads of grass-roots party organizations and all party members of the group headquarters to learn and convey the spirit of the 15th party congress of the communist party of China in Zhejiang province.
2022
07-24
On the morning of July 1, more than 40 members of the group's party committee, party members of various branches of the group headquarters, and party members of subordinate enterprise branches went to the Shuanglong Hydropower Station, the Red Education Base of Jinhua City, to receive party spirit and revolutionary tradition education.
2022
07-14
Vocational skill level identification examination!
On June 16 and 18, the theoretical and practical examinations for the determination of professional skill level in the peak pharmaceutical sector were held successively in Jinxi pharmaceutical factory. The independent identification of vocational skill level includes three occupations (types of work): pharmaceutical preparation worker, chemical inspector and organic synthesis worker, basically covering the main posts in the pharmaceutical sector, with a total of 125 employees signing up for the identification.
2022
06-21
On June 16, the Jianfeng Pharmaceutical Quality Research and Development Party Branch and the Jinhua Vocational Skills Management Service Center Party Branch held a signing ceremony in Jinxi Factory to establish a party building alliance.
2022
06-21
Jinhua Mayor Xing Zhihong to Peak Research
On the afternoon of June 1, Jinhua Mayor Xing Zhihong, Wucheng District Party Committee Secretary Gao Feng, District Mayor Hu Yuxian, and heads of the Municipal Economic and Information Bureau, Development and Reform Bureau and other departments went to the group headquarters to discuss and exchange with the leaders of the group company to understand the development of the enterprise. Solicit opinions and suggestions from enterprises on government work. After understanding the current business situation of the peak, Xing Zhihong pointed out that focus, follow the right path, frontier, steady, is the peak to long-term prosperity of the magic weapon, must continue to adhere.
2022
06-13
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page